BCMA-CD19 CAR-T for Refractory Inflammatory Myopathy
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This trial tests a new type of cell therapy (BCMA-CD19 cCAR-T) for people with inflammatory myopathy that hasn't improved with standard treatments. The goal is to see if this treatment can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You must have a type of inflammatory myopathy (like dermatomyositis or necrotizing myopathy) confirmed by a doctor and specific antibody tests.
- Your disease must be 'refractory,' meaning you've tried high-dose steroids, IVIG, and at least two other immune-suppressing drugs for over 6 months without success.
- You should have some muscle weakness (MMT-8 score of 141 or less) and elevated muscle enzymes (at least 1.5 times normal).
- You cannot have active infections, severe organ problems (heart, kidney, liver, or bone marrow), or a history of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (GC012F) for people with idiopathic inflammatory myopathy (IIM) that hasn't responded to standard treatments. It aims to see if this treatment can help control muscle inflammation and weakness.
This trial tests a new treatment using modified immune cells (CAR-T cells) to reduce inflammation in people with moderate to severe inflammatory bowel disease (IBD) that hasn't improved with other advanced treatments.
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
This trial tests a new treatment called Eque-cel, which uses your own immune cells to target and destroy the cells causing muscle damage. It is for people with a specific type of inflammatory muscle disease that has not improved with standard treatments.
This study tests a new immune therapy called CAR T-cells (KYV-101) for people with active, tough-to-treat dermatomyositis. It aims to see if the treatment is safe and can reduce muscle weakness and skin rash.
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
Hear when a new Inflammatory Myopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.